Praxis Precision Medicines (PRAX) EBITDA (2019 - 2026)

Praxis Precision Medicines has reported EBITDA for 8 years, with the latest figure at -$94.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 36.7% year-over-year to -$94.7 million; the trailing twelve-month figure through Mar 2026 stood at -$346.2 million (down 52.12% YoY), and the FY2025 full-year result was -$326.2 million, down 62.96% from the prior year.
• EBITDA for Q1 2026 stood at -$94.7 million, up from -$97.0 million in the prior quarter.
• The five-year high for EBITDA was -$25.5 million in Q3 2023, with the low at -$97.0 million in Q4 2025.
• Average EBITDA over 5 years is -$56.3 million, with a median of -$56.8 million recorded in 2024.
• Year-over-year, EBITDA tumbled 151.82% in 2022 and soared 44.91% in 2023.
• Tracing PRAX's EBITDA over 5 years: stood at -$41.5 million in 2022, then jumped by 32.92% to -$27.8 million in 2023, then slumped by 130.01% to -$64.0 million in 2024, then tumbled by 51.74% to -$97.0 million in 2025, then advanced by 2.4% to -$94.7 million in 2026.
• The last three EBITDA figures came in at -$94.7 million (Q1 2026), -$97.0 million (Q4 2025), and -$78.4 million (Q3 2025), per Business Quant data.

Peer Comparison